BioCentury | Feb 5, 2021
Management Tracks

Chugai names Okuda CEO; plus Astellas promotes Barretto-Ko to CBO, Goto to CSO and updates from Merck KGaA, Scholar Rock, Berkeley Lights, Catamaran and more

...commercial officer. The epigenetic blood test company also promoted Gaetan Michel, CEO of its Belgian Volition...
BioCentury | Jan 24, 2019
Tools & Techniques

Mapping symptoms to brain circuits

...are involved in human free will based on brain lesions that get rid of our volition...
BioCentury | Oct 12, 2018
Targets & Mechanisms

Adult path for mitochondrial gene editing

...the mitochondria. “The guide does not necessary have to get to mitochondria of its own volition...
BioCentury | Dec 1, 2016
Financial News

TraceLink completes venture financing

...$51.5 million in a series C round led by Goldman Sachs Growth Equity. FirstMark Capital, Volition...
BioCentury | Nov 30, 2016
Financial News

TraceLink raises $51.5M in series C round

...million series C round led by Goldman Sachs Growth Equity. Also participating were FirstMark Capital, Volition...
BioCentury | Oct 17, 2011
Company News

Volition, Standard Capital Corp. deal

...Diagnostic company Volition completed its reverse-merger with Standard Capital. Standard Capital has filed to change the...
...to VolitionRx Ltd. and VOLN on the OTC Bulletin Board, respectively (see BioCentury, Oct. 3). Singapore Volition Pte. Ltd....
BioCentury | Oct 3, 2011
Company News

Volition, Standard Capital deal

...Volition shareholders will exchange 6.9 million shares for Standard Capital shares at a 1-for-1 ratio. Volition...
...The combined company will develop Volition's blood-based cancer diagnostics. The reverse merger is subject to Volition...
...Volition is expected to hold about an 11% stake in VolitionRx (see BioCentury, June 20). Singapore Volition Pte. Ltd....
BioCentury | Jun 20, 2011
Company News

Volition, ValiRx deal

...Belgian cancer diagnostics subsidiary, ValiBIO S.A., to Volition. Volition will issue an additional $510,000 in Volition...
...a patent covering hypergenomics technology. Volition originally received rights to the technology through a sublicense. Volition...
...Volition for $400,000 in cash and $600,000 in Volition shares (see BioCentury, Oct. 18, 2010). Singapore Volition Pte. Ltd....
BioCentury | Oct 18, 2010
Company News

Volition, ValiRx deal

...to Volition for $400,000 in cash and $600,000 in Volition shares (see BioCentury, Oct. 4). Singapore Volition Pte. Ltd....
BioCentury | Oct 4, 2010
Company News

Singapore Volition Pte. Ltd., ValiRx deal

...diagnostics subsidiary, ValiBIO S.A., to Volition for $400,000 in cash and $600,000 in Volition shares. Volition...
...of the deal, George Morris will step down as ValiRx's COO to become CEO of Volition...
...step down as a ValiRx director but will remain as a technical officer with ValiRx. Singapore Volition Pte. Ltd....
Items per page:
1 - 10 of 10
BioCentury | Feb 5, 2021
Management Tracks

Chugai names Okuda CEO; plus Astellas promotes Barretto-Ko to CBO, Goto to CSO and updates from Merck KGaA, Scholar Rock, Berkeley Lights, Catamaran and more

...commercial officer. The epigenetic blood test company also promoted Gaetan Michel, CEO of its Belgian Volition...
BioCentury | Jan 24, 2019
Tools & Techniques

Mapping symptoms to brain circuits

...are involved in human free will based on brain lesions that get rid of our volition...
BioCentury | Oct 12, 2018
Targets & Mechanisms

Adult path for mitochondrial gene editing

...the mitochondria. “The guide does not necessary have to get to mitochondria of its own volition...
BioCentury | Dec 1, 2016
Financial News

TraceLink completes venture financing

...$51.5 million in a series C round led by Goldman Sachs Growth Equity. FirstMark Capital, Volition...
BioCentury | Nov 30, 2016
Financial News

TraceLink raises $51.5M in series C round

...million series C round led by Goldman Sachs Growth Equity. Also participating were FirstMark Capital, Volition...
BioCentury | Oct 17, 2011
Company News

Volition, Standard Capital Corp. deal

...Diagnostic company Volition completed its reverse-merger with Standard Capital. Standard Capital has filed to change the...
...to VolitionRx Ltd. and VOLN on the OTC Bulletin Board, respectively (see BioCentury, Oct. 3). Singapore Volition Pte. Ltd....
BioCentury | Oct 3, 2011
Company News

Volition, Standard Capital deal

...Volition shareholders will exchange 6.9 million shares for Standard Capital shares at a 1-for-1 ratio. Volition...
...The combined company will develop Volition's blood-based cancer diagnostics. The reverse merger is subject to Volition...
...Volition is expected to hold about an 11% stake in VolitionRx (see BioCentury, June 20). Singapore Volition Pte. Ltd....
BioCentury | Jun 20, 2011
Company News

Volition, ValiRx deal

...Belgian cancer diagnostics subsidiary, ValiBIO S.A., to Volition. Volition will issue an additional $510,000 in Volition...
...a patent covering hypergenomics technology. Volition originally received rights to the technology through a sublicense. Volition...
...Volition for $400,000 in cash and $600,000 in Volition shares (see BioCentury, Oct. 18, 2010). Singapore Volition Pte. Ltd....
BioCentury | Oct 18, 2010
Company News

Volition, ValiRx deal

...to Volition for $400,000 in cash and $600,000 in Volition shares (see BioCentury, Oct. 4). Singapore Volition Pte. Ltd....
BioCentury | Oct 4, 2010
Company News

Singapore Volition Pte. Ltd., ValiRx deal

...diagnostics subsidiary, ValiBIO S.A., to Volition for $400,000 in cash and $600,000 in Volition shares. Volition...
...of the deal, George Morris will step down as ValiRx's COO to become CEO of Volition...
...step down as a ValiRx director but will remain as a technical officer with ValiRx. Singapore Volition Pte. Ltd....
Items per page:
1 - 10 of 10